This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
The content of this website has been produced in line with the INLYTA® (axitinib) Summary of Product Characteristics for Great Britain.
Prescribing Information for INLYTA® (axitinib) click here. Prescribing Information for SUTENT® (sunitinib malate) click here. Adverse event reporting information can be found at the bottom of the page.
ByYourSideTM is a programme created by Pfizer Oncology that provides tools to help cancer patients manage their lives, regardless of tumour type or stage, as well as resources to support their loved ones. These resources can be downloaded using the QR code below or via the App Store and Google Play Store.
Life with cancer is different for everyone. There are many ways that patients go about their lives after a diagnosis. Patients can visit ByYourSide™ to read inspiring stories of hope, determination and generosity.
Patients can visit ByYourSide.co.uk or download the ByYourSideTM app to browse articles and resources designed to help them navigate and manage life with cancer.
Help your patients connect to their wellbeing with articles on relationships, nutrition, fitness and more.
Discover more about how ByYourSideTM can help your patients
Reference
INLYTA® is indicated for the treatment of adult patients with advanced renal cell carcinoma (aRCC) after failure of prior treatment with sunitinib or a cytokine.1
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021